The Companies announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
The Company will provide an overview of its business at the Craig-Hallum Institutional Investor Conference and the Stifel Dental & Veterinary Conference.
The Company announced its first quarter 2014 financial results and plans to host a conference call May 13, 2014 at 4:45 p.m. ET.
The Company announced the initiation of the pivotal field effectiveness study for AT-001 (grapiprant), the company’s innovative drug for treating pain in dogs with osteoarthritis.
The Company will host a conference call and live audio webcast on Tuesday, May 13, 2014 at 4:45 p.m. ET to discuss its financial results for the quarter ended March 31, 2014.
The Company announced its presentation plans for the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum to be held June 4-7, 2014 in Nashville.
The Company announced the appointment of former Theravance executive David L. Brinkley to its Board of Directors.
The Company announced a global licensing agreement for Advaxis’ ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.
The Company announced its fourth quarter and full year 2013 financial results and plans to host a conference call on March 13, 2014 at 8 a.m. ET.
The Company will host a conference call and live audio webcast on Thursday, March 13, 2014 at 8:00 a.m. ET to discuss its financial results for the quarter ended December 31, 2013.
The Company announced that it will present at the Barclays Global Healthcare Conference to be held March 11-13, 2014, in Miami, Florida and also at the Jefferies Animal Health Day on March 27, 2014 in New York City.
The Company announced the addition of Laura Brege, President and Chief Executive Office of Nodality, Inc., and Merilee Raines, former Executive Vice President and Chief Financial Officer of IDEXX Laboratories, to its Board of Directors.
The Company announced the upsizing and pricing of its previously announced public offering.
The Company announced the full exercise of the underwriters’ option to purchase 975,000 additional shares of common stock in connection with the company’s previously announced public offering of 6,500,000 shares of common stock.
The Company announced that the United States Department of Agriculture (USDA) has granted conditional approval for AT-005, Aratana’s canine-specific monoclonal antibody against CD52, which is intended as an aid in the treatment of T-cell lymphoma in dogs.
The Company announced that it is commencing an underwritten registered public offering of 5,500,000 shares of its common stock.
The Company announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases.